thalidomide has been researched along with delanzomib in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Appel, A | 1 |
| Berenson, JR; Chen, H; Hunter, K; Jones-Bolin, S; Li, J; Li, M; Ruggeri, B; Sanchez, E; Wang, C | 1 |
3 other study(ies) available for thalidomide and delanzomib
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Drugs: More shots on target.
Topics: Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; Glycine; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oligopeptides; Protease Inhibitors; Pyrazines; Survival Rate; Thalidomide; Threonine | 2011 |
CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Cell Line, Tumor; Dexamethasone; Humans; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Thalidomide; Threonine; Xenograft Model Antitumor Assays | 2012 |